Powering the Future of Diagnostics PHTA’s first resident, KIFFIK Biomedical, is changing the diagnostics landscape with a needle-free, interstitial fluid (ISF)-based diagnostic platform, the KIFFIK Lab™ – offering fast, accurate, and at-home disease detection. Now, through strategic partnerships with Duracell and Rubix, KIFFIK is accelerating the next generation of biomarker-driven diagnostics. These collaborations, supported by the PHTA ecosystem, are not just advancing cancer screening but also opening doors for broader industry innovation. “At KIFFIK, we believe that the future of diagnostics lies in harnessing the rich biomarker profile of interstitial …
[Providence, RI, 03/20/2025] – Kiffik Biomedical, a leader in interstitial fluid (ISF)-based diagnostics, has announced a strategic partnership with Rubix LS, a pioneer in aptamer-based precision medicine, to develop a first-of-its-kind rapid colorectal cancer test. This collaboration combines KIFFIK’s groundbreaking ISF biomarker collection technology with Rubix LS’s advanced aptamer detection platform, offering an innovative, non-invasive alternative to traditional screening methods. Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, yet screening adherence remains low due to invasive procedures, discomfort, and stigma. By leveraging ISF-based biomarker detection and …
Duracell® batteries will be integrated into KIFFIK Biomonitoring Devices, such as health monitors, that detect various biomarkers in the body. [Providence, RI, 01/29/2025] – KIFFIK Biomedical and Duracell U.S. Operations, Inc. (“Duracell”) have agreed to collaborate and assess the integration of long-lasting, efficient power solutions with cutting-edge biomonitoring technology. This is good news for patients and the public communities, as the partnership’s goal is to enhance the precision and dependability of health monitoring systems around the globe, ultimately benefitting users in hospitals, high-performance sports, the military, and at home with …
KIFFIK Biomedical secures a pivotal $50 million investment from GEM Global Yield, positioning the company as a ‘Unicorn-in-Waiting’ KIFFIK’s patented platform will disrupt current MedTech markets by offering real-time insights and personalized care in a way that was previously unimaginable while allowing healthcare professionals to fully diagnose, monitor, and more extensively treat patients remotely. Read More > “I’m excited to announce a major milestone for KIFFIK Biomedical. We want to thank our new partners GEM, as we continue to deliver on our mission of bringing promising new diagnostic advancements to …
The interstitial space is the primary source of lymph and is a major fluid compartment in the body. While the anatomy and composition of the interstitial space between cells is increasingly understood, the existence, location, and structure of larger inter- and intra-tissue spaces is described only vaguely in the literature.
For the first time, extraction of bio-rich interstitial fluid (IF) with all its components will be available for multiple health applications. This addition to the medical professional’s toolkit opens the door to a range of opportunities. For scientists, physicians, veterinarians, and hospital professionals, there is the chance to perform continuous or periodic monitoring of critical biomarkers that are prevalent in diseases. The information learned from this fluid can help clinicians, researchers, and biopharmaceutical developers overcome the limitations of plasma and serum monitoring.
*THe KIFFIK Lab is not FDA cleared. For investigational use only.
Embedded Sources:
Yahoo Finance & Bloomberg (April 2025)
McKinsey Biopharma Report (2024)
Grad View Research Diagnostics Report (2024)
Nature Reviews Drug Discovery (2024)
Science Translational Medicine (2023)
EvaluatePharma World Preview (2024)
Nature Biotechnology (2023)
Global Market Insights (2023)
BCG Diagnostics Landscape (2024)
Statista Health Forecasts (2025)
Use Case: Women's Health
Empowering Women with Real-Time Hormonal Insight.
The challenge.
Millions of women struggle with hormone-related health issues, from irregular cycles and fertility challenges to menopause and hormone-sensitive conditions. Yet hormone levels are dynamic, and current tests offer only static snapshots, often missing key changes or trends.
The opportunity.
KIFFIK’s ISF platform could continuously or intermittently monitor hormones like estrogen, progesterone, and LH in a non-invasive, user-friendly way. This opens the door to proactive management of fertility, cycle regulation, and personalized hormonal therapies — all without frequent lab visits.
Clinical application:
Real-time ovulation tracking and cycle phase identification
Monitoring hormone replacement therapy in menopause
Early detection of hormonal imbalances (e.g., PCOS, amenorrhea)
Potential biomoarkers:
Estradiol (E2)
Luteinizing Hormone (LH)
Progesterone
Follicle-Stimulating Hormone (FSH)
Anti-Müllerian Hormone (AMH)
Hormonal health shouldn’t be a guessing game. With KIFFIK, women can see their cycle, and their care, more clearly than ever before.
Use Case: Military & PolyTrauma
Field-ready diagnostics for high-consequence decisions.
The challenge.
In military and trauma settings, rapid diagnosis can mean the difference between life and loss. Yet current tools often require centralized labs, invasive procedures, or lag-time results — none of which are ideal in field, combat, or mass casualty environments.
The opportunity.
KIFFIK’s non-invasive ISF platform could deliver real-time biomarker data directly at the point of injury — enabling rapid triage, injury stratification, and early detection of complications like internal bleeding, systemic inflammation, or infection. Designed for portability and ease of use, the platform can support frontline teams with fast, actionable insight.
Clinical application:
Triage of blast injuries, blunt trauma, and polytrauma
Early detection of inflammatory cascade and internal bleeding
Remote deployment in field hospitals, medevac, or battlefield medicine
Potential biomoarkers:
Interleukin-6 (IL-6)
S100B (neurotrauma indicator)
Lactate (tissue hypoxia)
D-dimer (coagulation dysfunction)
Myoglobin (muscle damage)
TNF-α (systemic inflammation)
When every second counts, insight can’t wait for the hospital. KIFFIK’s platform is designed to move with the mission — delivering data where it’s needed most.
Use Case: Prostate Cancer
Precision Monitoring for a Leading Men’s Health Challenge
The challenge.
Prostate cancer is the second most common cancer in men globally. Yet current monitoring tools, like PSA blood tests or invasive biopsies, often lack specificity, are performed infrequently, and can lead to overtreatment or missed progression. Clinicians need better tools to distinguish between indolent and aggressive disease in real time.
The opportunity.
KIFFIK’s non-invasive ISF platform offers continuous or on-demand biomarker monitoring that could detect early biochemical changes associated with disease onset, progression, or treatment response. By bypassing the need for repeated blood draws or delayed lab tests, the platform supports personalized surveillance strategies and more confident clinical decisions.
Clinical application:
Early detection and screening for high-risk populations
Monitoring treatment efficacy and therapeutic resistance
Active surveillance of low-risk prostate cancer without invasive biopsies
Potential biomoarkers:
Prostate-Specific Antigen (PSA)
PCA3 (Prostate Cancer Antigen 3)
Alpha-methylacyl-CoA racemase (AMACR)
Circulating tumor DNA (ctDNA) for mutation profiling
Interleukin-8 (IL-8) and other inflammation markers
Continuous insight without constant disruption, KIFFIK’s platform enables smarter, patient-centered care for prostate cancer across the spectrum of disease.
ISF Research & Biomarker Discovery
Accelerating discovery from tissue to therapy.
The challenge.
Biomarker discovery is central to advancing precision medicine, but most research depends on invasive blood sampling or static lab tests. These limitations reduce sampling frequency, overlook localized biological signals, and make real-world longitudinal data difficult to obtain. Critical biomarkers can remain undetected, or misunderstood, without a more accessible and dynamic sampling medium.
The opportunity.
KIFFIK Lab offers scalable, repeatable access to interstitial fluid (ISF), providing researchers with a unique window into tissue-adjacent biology. By enabling real-time collection of molecular data, without blood draws, KIFFIK transforms how biomarkers are discovered, validated, and monitored. Our platform supports translational research across therapeutic areas with minimal burden on participants.
Clinical application:
Early-phase biomarker discovery in immune, metabolic, and oncologic pathways
Pharmacodynamic and pharmacokinetic profiling in clinical trials
Companion diagnostic development in personalized medicine
Population-scale studies using decentralized, non-invasive sampling
Potential biomoarkers:
IL-6, CRP (inflammatory signaling)
Adiponectin, leptin (metabolic regulation)
VEGF, IL-8 (oncogenic pathways)
S100B, GFAP (neuroinflammatory injury)
Every breakthrough begins with better data. KIFFIK gives researchers a new lens on human biology, continuously, painlessly, and in real time.
Use Case: Sepsis
Catching the cascade before it crashes the system.
The challenge.
Sepsis progresses rapidly and often invisibly in its early stages. Current diagnostic tools rely on lagging indicators or generalized clinical signs, leaving critical intervention windows missed.
The opportunity.
KIFFIK’s platform offers the potential to detect sepsis-associated biomarkers in ISF at the earliest stages of dysregulation. This enables real-time insight into immune response and systemic inflammation — allowing for faster, more targeted intervention when it’s most needed.
Clinical application:
Emergency departments
ICUs and high-risk inpatient settings
Resource-limited environments and field hospitals
Potential biomoarkers:
Procalcitonin (PCT)
C-reactive protein (CRP)
Interleukin-6 (IL-6)
TNF-α (Tumor Necrosis Factor-alpha)
Lactate
When sepsis moves fast, we have to move faster. KIFFIK’s platform could help detect the warning signs before symptoms spiral.
Use Case: Skin Health
Turning the surface into a source of insight.
The challenge.
Skin is the body’s largest organ — and one of the most visible — yet its health is often assessed only through surface observation or delayed biopsies. Whether in dermatology clinics or personal care, there’s limited access to underlying biological signals that reveal what’s really happening beneath the surface.
The opportunity.
By accessing biomarkers directly from interstitial fluid within the skin, KIFFIK’s platform may unlock real-time, molecular-level insight into inflammation, immune activity, and cellular stress. This supports both clinical care and proactive skin wellness — from chronic disease management to personalized skincare.
Clinical application:
Dermatology: Non-invasive assessment of skin inflammation, disease flares (e.g., eczema, psoriasis), and potentially early indicators of melanoma or other skin cancers
Beauty & Wellness: Real-time monitoring of skin barrier integrity, hydration, oxidative stress, and treatment response for personalized skincare routines
Potential biomoarkers:
Interleukin-1α (IL-1α)
Interleukin-8 (IL-8)
TNF-α
MMP-9 (Matrix metalloproteinase-9)
Reactive oxygen species (ROS)
Natural moisturizing factor (NMF) markers
The skin is always speaking — through irritation, inflammation, and subtle shifts. With ISF, we can finally hear it clearly, and respond in real time.
Use Case: Traumatic Brain Injury (TBI)
Real-time insight into invisible injuries
The challenge.
TBI often presents without visible symptoms, especially in early stages. Traditional tools like imaging and clinical exams can miss subtle, evolving changes — delaying care when time is critical.
The opportunity.
Through interstitial fluid, KIFFIK’s platform may enable early detection of TBI by capturing biomarker signals linked to inflammation, neurotrauma, and cellular stress. This could transform how we identify and manage brain injury — from emergency departments to military and athletic settings.
Clinical application:
Emergency medicine
Sports concussion protocols
Military and remote triage
Potential biomoarkers:
GFAP (Glial Fibrillary Acidic Protein)
UCH-L1 (Ubiquitin C-terminal hydrolase L1)
S100B
Interleukin-6 (IL-6)
Tau protein fragments
Early detection of brain injury doesn't have to wait for imaging. With ISF, it could happen in minutes — where it matters most.
Use Case: Colorectal Cancer
Early detection without delay — or discomfort.
The challenge.
Colorectal cancer is the second leading cause of cancer-related deaths, yet screening rates remain low due to fear, discomfort, and the invasiveness of traditional tests. Many cases go undetected until advanced stages, when outcomes are poorer and costs are higher.
The opportunity.
KIFFIK Lab delivers a non-invasive, point-of-care test for colorectal cancer screening — offering a patient-friendly alternative to colonoscopy, blood draws, and stool-based tests. By accessing ISF biomarkers through the skin, our platform enables earlier insight, faster decision-making, and broader screening access.
Clinical application:
Routine screening in primary care and outpatient settings
Non-invasive option for screening-hesitant populations
Expanded access for underserved and remote communities
Potential biomoarkers:
Carcinoembryonic antigen (CEA)
Methylated DNA markers (e.g., SEPT9)
MMP-9 (Matrix metalloproteinase-9)
Interleukin-8 (IL-8)
Calprotectin (inflammatory marker)
Colorectal cancer can be prevented — if it's detected early. KIFFIK makes screening simpler, faster, and more human.